Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: National differences

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 7, 2005, Pages 339-349

  Zullino, D ^a   Mayland, G ^a   Schmidt, L G ^b   Fahndrich E ^c   Greil, W ^d   Horvath, A ^d   Ruther E ^e   Engel, R ^f   Hippius, H ^f   Baumann, Pierre ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^d Psychiat Privatklinik   (Switzerland)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Drug prescription; Psychiatric hospitals; Psychiatric patients; Psychotropic drugs

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; REBOXETINE; RISPERIDONE; SERTRALINE; VENLAFAXINE;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DELUSIONAL DISORDER; DRUG DEPENDENCE; DRUG PREFERENCE; DRUG USE; ECONOMIC ASPECT; FEMALE; GENDER; GEOGRAPHY; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; MOOD DISORDER; NEUROSIS; PRESCRIPTION; PROFESSIONAL PRACTICE; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SWITZERLAND;

EID: 22144431903     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43339     Document Type: Article

References (56)

1. Ambühl B, Würmle O, Michel G 1993 Die Verschreibungspraxis von Psychopharmaka in einer psychiatrischen Universitätsklinik. Psychiatr Prax 20: 70-73
2. Aronson SM 1997 Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clin Ther 19: 139-147
3. Association of researching drug makers 2004 Deficits in the supply of drugs in Germany, p 13. Institute of medical statistics (VFA, Verband forschender Arzneimittelhersteller. Defizite in der Arzneimittelversorgung in Deutschland Institut für Medizinische Statistik IMS Health, p 13
4. Baldessarini RJ, Kando JC, Centorrino F 1995 Hospital use of antipsychotic agents in 1989 and 1993: Stable dosing with decreased length of stay. Am J Psychiatry 152: 1038-1044
5. Biscay ML, Saint-Martin F 1998 Enquête de pratiques, sur le profil médicamenteux des patients ambulatoires en psychiatrie. Nervure 11: 13-16
6. Byrom BD, Garratt U, Kilpatrick AT 1998 Influence of antipsychotic profile on cost of treatment of schizophrenia: a decision analysis approach. Int J Psychiatry Clin Pract 2: 129-138
7. Clark AF, Holden NL 1987 The persistence of prescribing habits: a survey and follow-up of prescribing to chronic hospital in-patients. Br J Psychiatry 150: 88-91
8. Crott R, Gillis P 1998 Economic comparisons of the pharmacotherapy of depression: an overview. Acta Psychiatr Scand 97: 241-252
9. Diamond H, Tislow R, Snyder T, Rickels K 1976 Peer review of prescribing patterns in a CMHC. Am J Psychiatry 133: 697-699
10. Edwards S, Kumar V 1984 A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital. Br J Psychiatry 145: 502-507
11. Egberts ACG, Veenstra M, de Jong-van den Berg LTW 1999 Antidepressant drug choice for first users in two regions in The Netherlands. Pharm World Sci 21: 132-136
12. Fombonne E, Mousson F, Dassonville B et al 1989 Étude des prescriptions de médicaments psychotropes dans un hôpital psychiatrique français. Rev Epidém et Santé Publ 37: 29-36
13. Foster R, Goa KL 1999 Olanzapine: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 15: 611-640
14. Glazer WM, Johnstone BM 1997 Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 58: 50-54
15. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER 1993 The economic burden of depression in 1990. J Clin Psychiatry 54: 405-418
16. Grohmann R, Rüther E, Engel RR, Hippius H 1999 Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 32: 21-28
17. Helgason T, Björnsson JK, Zoëga T, Thorsteinsson HS, Tómasson H 1997 Psychopharmacology in Iceland: effects of regulations and new medications. Eur Arch Psychiatry Clin Neurosci 247: 93-99
18. Herbold M 1997 International guidelines on post-authorisation research and surveillance. Pharmacopsychiatry 30: 62-64
19. Knapp M 1997 Costs of schizophrenia. Br J Psychiatry 171: 509-518
20. Knapp M, Kavanagh S 1997 Economic outcomes and costs in the treatment of schizophrenia. Clin Ther 19: 128-138
21. Knapp M 1998 Measuring the economic benefit of treatment with atypical antipsychotics. Eur Psychiatry 13: 37s-45s
22. Laux G, König W 1987 Long-term use of benzodiazepines in psychiatric inpatients. Acta Psychiatr Scand 76: 64-70
23. Laux G, Baier D 1997 Quality-monitoring of psychotropic drug therapy in post-marketing surveillance. Pharmacopsychiat 30: 21-27
24. Le Pen C, Lilliu H, Allicar MP, Olivier V, Gregor KJ 1999 Compairison économique de l'olanzapine versus halopéridol dans le traitement de la schizophrénie en France. Encéphale 25: 281-286
25. Linden M 1997 Phase IV research and drug utilization observation studies. Pharmacopsychiatry 30: 1-3
26. Linden M, Lecrubier Y, Bellantuono C, Benkert O, Kisely S, Simon G 1999 The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. J Clin Psychopharmacol 19: 132-140
27. Lippert E, Aigner JM, Grohmann R, Klein HE, Schmauss M, Rüther E 1996 Anwendungshäufigkeiten und Dosierungen von Psychopharmaka an psychiatrischen Versorgungskrankenhäusern - Ergebnisse aus dem Arzneimittelüberwachungsprojekt Bayern. Psychopharmakotherapie 3: 178-183
28. Mamdani MM, Parikh SV, Austin PC, Upshur REG 2000 Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 157: 360-367
29. Michel K, Kolakowska T 1981 A survey of prescribing psychotropic drugs in two psychiatric hospitals. Br J Psychiatry 138: 217-221
30. Montgomery SA, Kasper S 1998 Side effects, dropouts from treatment and cost consequences. Int Clin Psychopharmacol 13: S1-S5
31. Morgan R, Gopalaswamy AK 1984 Psychotropic drugs: another survey of prescribing patterns. Br J Psychiatry 144: 298-302
32. Morris S, Hogan T, McGuire A 1998 The cost-effectiveness of clozapine. Clin Drug invest 15: 137-152
33. Muijen M, Silverstone T 1987 A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 150: 501-504
34. Nichol MB, Stimmel GL, Lange SC 1995 Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry 56: 60-66
35. Nuijten M, Hadjadjeba L, Evans C, van den Berg J 1998 Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 14: 433-445
36. Olfson M, Pincus HA, Dial TH 1994 Professional practice patterns of US psychiatrists. Am J Psychiatry 151: 89-95
37. Panzarino PJ 1998 The costs of depression: direct and indirect; treatment versus nontreatment. J Clin Psychiatry 59: 11-14
38. Pincus HA, Tanielian TL, Marcus SC et al 1998 Prescribing trend in psychotropic medications: primary care, psychiatry, and other medical specialities. JAMA 279: 526-531
39. Pincus HA, Zarin DA, Tanielian TL et al 1999 Psychiatric patients and treatments in 1997. Arch Gen Psychiatry 56: 441-449
40. Procyshyn RM, Zerjav S 1998 Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Ther 20: 1203-1217
41. Reid WH 1999 New vs. old antipsychotics: the Texas experience. J Clin Psychiatry 60: 23-25
42. Revicki DA 1999 Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. J Clin Psychiatry 60: 7-11
43. Rice DP 1999 The economic impact of schizophrenia. J Clin Psychiatry 60: 4-6
44. Rittmansberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H 1999 Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14: 33-40
45. Rosholm JU, Gram LF, Hallas J, Bergman U 1997 Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 52: 205-209
46. Schäfer H 1997 Post-approval drug research: objectives and methods. Pharmacopsychiat 30: 4-8
47. Schmidt LG, Niemeyer R, Müller-Oerlinghausen B 1983 Drug prescribing pattern of a psychiatric university hospital in Germany. Pharmacopsychiatry 16: 35-42
48. Schmidt LG, Lammers V, Stöckel M, Müller-Oerlinghausen B 1988 Recent trends in prescribing psychotropic drugs at a psychiatric university hospital (1981-84). Pharmacopsychiatry 21: 126-130
49. Sirey JA, Meyers BS, Bruce ML, Alexopoulos GS, Perlick DA, Raue P 1999 Predictors of antidepressant prescription and early use among depressed outpatients. Am J Psychiatry 156: 690-696
50. Tylee A 1999 Depression in the community: physician and patient perspective. J Clin Psychiatry 60: 12-16
51. Viale GL 1998 An economic analysis of physicians' prescribing of selective serotonin reuptake inhibitors. Hosp Pharm 33: 847-850
52. Voirol P, Robert PA, Meister P, Oros L, Baumann P 1999 Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 32: 29-37
53. Zito JM 1998 Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatry Clin North Am 21: 181-202
54. Zullino D, Bondolfi G, Baumann P 1998 The serotonin paradox: negative symptoms and SSRI augmentation. Int J Psychiatry Clin Pract 2: 19-26
55. Zullino D, Baumann P, Grohmann R, Greil W 2000 L'importance de la pharmacovigilance en psychiatrie - Le Projet AMSP (Arzneimittelsicherheit in der Psychiatrie). Rev Med Suisse Romande 120: 105-109
56. Zullino D, Baumann P 2001 Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34: 1-9